Gallium maltolate inhibits human cutaneous T-cell lymphoma tumor development in mice

Journal of Investigative Dermatology

Volumn 135, Issue 3, 2015, Pages 877-884

  Wu, Xuesong ^a   Wang, Timothy W ^a   Lessmann, George M ^a   Saleh, Jamal ^a   Liu, Xiping ^a   Chitambar, Christopher R ^a   Hwang, Sam T ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; GALLIUM; GALLIUM MALTOLATE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 13; PROTEIN P53; UNCLASSIFIED DRUG; CYTOKINE; ORGANOMETALLIC COMPOUND; PYRONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER SIZE; CARCINOGENESIS; CONTROLLED STUDY; CUTANEOUS T CELL LYMPHOMA; CYTOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; ANIMAL; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; FEMALE; LYMPHOMA, T-CELL, CUTANEOUS; METABOLISM; PATHOLOGY; SKIN NEOPLASMS; TUMOR CELL LINE; VASCULARIZATION; XENOGRAFT;

ANIMALS; APOPTOSIS; CARCINOGENESIS; CELL LINE, TUMOR; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; HETEROGRAFTS; HUMANS; IN VITRO TECHNIQUES; LYMPHOMA, T-CELL, CUTANEOUS; MICE; ORGANOMETALLIC COMPOUNDS; PYRONES; SKIN NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84922673479     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2014.476     Document Type: Article

References (29)

1. Arenberg DA, Kunkel SL, Polverini PJ et al. (1996) Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J Exp Med 184:981-92
2. Asadullah K, Docke WD, Haeussler A et al. (1996) Progression of mycosis fungoides is associated with increasing cutaneous expression of interleukin-10 mRNA. J Invest Dermatol 107:833-7
3. Chitambar CR (2012) Gallium-containing anticancer compounds. Future Med Chem 4:1257-72
4. Chitambar CR (2010) Medical applications and toxicities of gallium compounds. Int J Environ Res Public Health 7:2337-61
5. Chitambar CR, Antholine WE (2013) Iron-Targeting antitumor activity of gallium compounds and novel insights into triapine((R))-metal complexes. Antioxid Redox Signal 18:956-72
6. Chitambar CR, Purpi DP, Woodliff J et al. (2007) Development of gallium compounds for treatment of lymphoma: Gallium maltolate, a novel hydroxypyrone gallium compound, induces apoptosis and circumvents lymphoma cell resistance to gallium nitrate. J Pharmacol Exp Ther 322:1228-36
7. Chitambar CR, Seigneuret MC, Matthaeus WG et al. (1989) Modulation of lymphocyte proliferation and immunoglobulin production by transferringallium. Cancer Res 49:1125-9
8. Chitambar CR, Zivkovic Z (1987) Uptake of gallium-67 by human leukemic cells: Demonstration of transferrin receptor-dependent and transferrinindependent mechanisms. Cancer Res 47:3929-34
9. Dranka BP, Benavides GA, Diers AR et al. (2011) Assessing bioenergetic function in response to oxidative stress by metabolic profiling. Free Radic Biol Med 51:1621-35
10. Exner M, Minar E, Wagner O et al. (2004) The role of heme oxygenase-1 promoter polymorphisms in human disease. Free Radic Biol Med 37:1097-104
11. Harper JW, Adami GR, Wei N et al. (1993) The p21 cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75:805-16
12. Harris WR, Pecoraro VL (1983) Thermodynamic binding constants for gallium transferrin. Biochemistry 22:292-9
13. Hensbergen PJ, Wijnands PG, Schreurs MW et al. (2005) The CXCR3 targeting chemokine CXCL11 has potent antitumor activity in vivo involving attraction of CD8+ T lymphocytes but not inhibition of angiogenesis. J Immunother 28:343-51
14. Huang Z, Higgins B, Foss F (2005) Activity of gallium nitrate in refractory peripheral T-cell lymphoma. Clin Lymphoma 6:43-5
15. Hwang ST, Janik JE, Jaffe ES et al. (2008) Mycosis fungoides and sezary syndrome. Lancet 371:945-57
16. Kvaloy S, Langholm R, Kaalhus O et al. (1984) Transferrin receptor and B-lymphoblast antigen-Their relationship to DNA synthesis, histology and survival in B-cell lymphomas. Int J Cancer 33:173-7
17. Larson SM, Rasey JS, Allen DR et al. (1980) Common pathway for tumor cell uptake of gallium-67 and iron-59 via a transferrin receptor. J Natl Cancer Inst 64:41-53
18. Mantovani A, Allavena P, Sica A et al. (2008) Cancer-related inflammation. Nature 454:436-44
19. Richardson DR, Kalinowski DS, Lau S et al. (2009) Cancer cell iron metabolism and the development of potent iron chelators as anti-Tumour agents. Biochim Biophys Acta 1790:702-17
20. Rouault JP, Falette N, Guehenneux F et al. (1996) Identification of BTG2, an antiproliferative p53-dependent component of the DNA damage cellular response pathway. Nat Genet 14:482-6
21. Salvador JM, Brown-Clay JD, Fornace AJ Jr (2013) Gadd45 in stress signaling, cell cycle control, and apoptosis. Adv Exp Med Biol 793:1-19
22. Serve H, Oelmann E, Herweg A et al. (1996) Inhibition of proliferation and clonal growth of human breast cancer cells by interleukin 13. Cancer Res 56:3583-8
23. Straus DJ (2003) Gallium nitrate in the treatment of lymphoma. Semin Oncol 30:25-33
24. Sugaya M, Miyagaki T, Ohmatsu H et al. (2012) Association of the numbers of CD163(+) cells in lesional skin and serum levels of soluble CD163 with disease progression of cutaneous T cell lymphoma. J Dermatol Sci 68:45-51
25. Tannenbaum CS, Tubbs R, Armstrong D et al. (1998) The CXC chemokines IP-10 and mig are necessary for IL-12-mediated regression of the mouse RENCA tumor. J Immunol 161:927-32
26. Volpert OV, Fong T, Koch AE et al. (1998) Inhibition of angiogenesis by interleukin 4. J Exp Med 188:1039-46
27. Wu X, Schulte BC, Zhou Y et al. (2014) Depletion of M2-like tumor-Associated macrophages delays cutaneous T-cell lymphoma development in vivo. J Invest Dermatol 134:2814-22
28. Wu X, Sells RE, Hwang ST (2011) Upregulation of inflammatory cytokines and oncogenic signal pathways preceding tumor formation in a murine model of T-cell lymphoma in skin. J Invest Dermatol 131:1727-34
29. Zhu N, Shao Y, Xu L et al. (2009) Gadd45-Alpha and Gadd45-gamma utilize p38 and JNK signaling pathways to induce cell cycle G2/M arrest in hep-G2 hepatoma cells. Mol Biol Rep 36:2075-85